Hematology/Oncology

Top Story

Aromatase inhibitors improve recurrence rates, survival in early breast cancer

August 28, 2015

The use of an aromatase inhibitor reduced breast cancer recurrence rates approximately 30% compared with tamoxifen, according to the results of a meta-analysis.

Further, use of an aromatase inhibitor for 5 years reduced 10-year breast cancer mortality rates approximately 15% compared with 5 years of tamoxifen, equating to an approximate 40% reduction compared with no treatment.

In the Journals

Researchers develop value-based framework for cancer drug pricing

August 27, 2015
Researchers have developed a framework for establishing value-based pricing for new oncology drugs that are entering the U.S. market.“Cancer drug prices have been…
In the Journals

Overall global health improving, years lived with disability rising

August 27, 2015
Around the world, the average life expectancy increased by more than 6 years between 1990 and 2013; however, individuals are spending more years than ever living with…
In the Journals

Daratumumab demonstrates single-agent activity in relapsed, refractory multiple myeloma

August 27, 2015
Daratumumab monotherapy appeared safe and effective for patients with heavily pretreated relapsed or refractory multiple myeloma, according to study results published in…

CMS votes unanimously to maintain Medicare's reimbursement rate for Cologuard CRC screening test

August 27, 2015
The CMS Advisory Panel on Clinical Diagnostic Laboratory Tests voted unanimously (11-0) to maintain Medicare’s current reimbursement rate of $492.72 for the…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
morganatic-roan
morganatic-roan